Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.

Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE.

Clin Cancer Res. 2019 May 15;25(10):3141-3151. doi: 10.1158/1078-0432.CCR-18-2953. Epub 2019 Feb 8.

PMID:
30737244
2.

Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.

George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY, Clayman GL.

J Clin Endocrinol Metab. 2015 Dec;100(12):E1550-9. doi: 10.1210/jc.2015-2690. Epub 2015 Oct 13.

3.

Development and characterization of six new human papillary thyroid carcinoma cell lines.

Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL.

J Clin Endocrinol Metab. 2015 Feb;100(2):E243-52. doi: 10.1210/jc.2014-2624. Epub 2014 Nov 26.

4.

Detection of thyroid cancer stem cells in papillary thyroid carcinoma.

Ahn SH, Henderson YC, Williams MD, Lai SY, Clayman GL.

J Clin Endocrinol Metab. 2014 Feb;99(2):536-44. doi: 10.1210/jc.2013-2558. Epub 2013 Dec 3.

5.

Src inhibitors in suppression of papillary thyroid carcinoma growth.

Henderson YC, Toro-Serra R, Chen Y, Ryu J, Frederick MJ, Zhou G, Gallick GE, Lai SY, Clayman GL.

Head Neck. 2014 Mar;36(3):375-84. doi: 10.1002/hed.23316. Epub 2013 Jun 1.

6.

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.

Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN.

Clin Cancer Res. 2011 Dec 1;17(23):7248-64. doi: 10.1158/1078-0432.CCR-11-0690. Epub 2011 Aug 25.

7.

Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF 3rd, Calvert VS, Fodale V, Wang J, Weber RS.

Am J Pathol. 2011 Feb;178(2):548-71. doi: 10.1016/j.ajpath.2010.10.044.

8.

Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.

Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, Schwartz DL, Bankson JA, Myers JN, Lai SY.

Clin Cancer Res. 2011 Apr 15;17(8):2281-91. doi: 10.1158/1078-0432.CCR-10-2762. Epub 2011 Jan 10.

9.

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.

Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL.

Mol Cancer Ther. 2010 Jul;9(7):1968-76. doi: 10.1158/1535-7163.MCT-10-0062. Epub 2010 Jun 29.

10.

Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040.

Henderson YC, Ahn SH, Clayman GL.

Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):347-54. doi: 10.1001/archoto.2009.17.

11.

High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.

Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, Clayman GL.

Clin Cancer Res. 2009 Jan 15;15(2):485-91. doi: 10.1158/1078-0432.CCR-08-0933.

12.

Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.

Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL.

Head Neck. 2009 May;31(5):625-34. doi: 10.1002/hed.21007.

13.

Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.

Henderson YC, Ahn SH, Kang Y, Clayman GL.

Clin Cancer Res. 2008 Aug 1;14(15):4908-4914. doi: 10.1158/1078-0432.CCR-07-1772.

14.

LBP-1b, LBP-9, and LBP-32/MGR detected in syncytiotrophoblasts from first-trimester human placental tissue and their transcriptional regulation.

Henderson YC, Frederick MJ, Wang MT, Hollier LM, Clayman GL.

DNA Cell Biol. 2008 Feb;27(2):71-9.

PMID:
18004979
15.

Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.

Henderson YC, Fredrick MJ, Clayman GL.

Arch Otolaryngol Head Neck Surg. 2007 Aug;133(8):810-5.

PMID:
17709622
16.

Human LBP-32/MGR is a repressor of the P450scc in human choriocarcinoma cell line JEG-3.

Henderson YC, Frederick MJ, Jayakumar A, Choi Y, Wang MT, Kang Y, Evans R, Spring PM, Uesugi M, Clayman GL.

Placenta. 2007 Feb-Mar;28(2-3):152-60. Epub 2006 May 30.

PMID:
16730372
17.

An effective method for removing ribosomal RNA during mRNA purification.

Henderson YC, Clayman GL.

Methods Cell Sci. 2000;22(4):253-5. No abstract available.

PMID:
11549937
18.
19.

Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas.

Henderson YC, Wang E, Clayman GL.

Laryngoscope. 1998 Oct;108(10):1553-6.

PMID:
9778300
20.

A simple and sensitive method for detecting adenovirus in serum and urine.

Henderson YC, Liu TJ, Clayman GL.

J Virol Methods. 1998 Mar;71(1):51-6.

PMID:
9628221
21.

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.

Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H.

J Clin Oncol. 1998 Jun;16(6):2221-32.

PMID:
9626224
22.

Interferon regulatory factor 1 induces the expression of the interferon-stimulated genes.

Henderson YC, Chou M, Deisseroth AB.

Br J Haematol. 1997 Mar;96(3):566-75.

PMID:
9054665
23.

Potential role of bcr-abl in the activation of JAK1 kinase.

Henderson YC, Guo XY, Greenberger J, Deisseroth AB.

Clin Cancer Res. 1997 Feb;3(2):145-9.

Supplemental Content

Loading ...
Support Center